Composition for treating testicular atrophy and preparation method thereof

A technique for testicular atrophy and composition, applied in the field of compositions for the treatment of testicular atrophy and the field of preparation thereof, can solve problems such as poor testicular atrophy effect, and achieve the effects of increasing effective factor concentration, enhancing therapeutic effect, and enhancing concentration efficiency

Pending Publication Date: 2022-04-22
天晴干细胞股份有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The present invention aims to solve the problem that the existing platelet-rich plasma is not effective in treating testicular atrophy, and provides a composition for treating testicular atrophy and a preparation method thereof

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating testicular atrophy and preparation method thereof
  • Composition for treating testicular atrophy and preparation method thereof
  • Composition for treating testicular atrophy and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0046] Specific embodiment 1: The composition for treating testicular atrophy in this embodiment includes platelet lysate (sPL) and BMSCs exosomes, and the volume ratio of platelet lysate and BMSCs exosomes is 1:1; The concentration of EGF factor was 631-674pg / mL, the concentration of bFGF factor was 86-107pg / mL, and the concentration of IGF-1 factor was 26-30ng / mL; the concentration of exosomal protein in BMSCs exosomes was 1 μg / μL.

specific Embodiment approach 2

[0047] Specific embodiment two: this embodiment is a further description of specific embodiment one: the preparation method of the platelet lysate is specifically:

[0048] Centrifuge the collected rat whole blood at a speed of 150-500×g for 15-20min, take the upper layer of plasma, and then centrifuge at a speed of 900-1300×g for 20-25min, and take the lower layer of platelet-rich plasma (PRP) to ensure the volume of the lower layer 1 / 10 of the volume of whole blood;

[0049] Addition of CaCl to prepared PRP 2 and type III collagen, stored at -80°C for 8 hours, then thawed at 37°C for 5 minutes, then repeated freezing and thawing 10 times, centrifuged the last thawed lysate at 3000×g for 15-20 minutes, and took the supernatant, which was sPL. Among them, CaCl in PRP 2 The concentration of PRP is 20-30mM, and the concentration of type III collagen in PRP is 15-35μg / mL. Others are the same as in the first embodiment.

[0050] In the preparation method of sPL in this embodi...

specific Embodiment approach 3

[0051] Embodiment 3: This embodiment is a further description of Embodiment 2: the conditions for repeated freezing and thawing are freezing at -80°C for 1 hour each time, and then thawing at 37°C for 5 minutes. Others are the same as in the second embodiment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a composition for treating testicular atrophy and a preparation method thereof, and relates to the field of medicines for treating testicular atrophy, in particular to a composition for treating testicular atrophy and a preparation method thereof. The invention aims to solve the problem of poor testicular atrophy treatment effect of the existing platelet-rich plasma. The composition comprises a platelet lysis buffer and a BMSCs exosome, and the volume ratio of the platelet lysis buffer to the BMSCs exosome is 1: 1. The platelet lysate sPL and the BMSCs exosome are prepared into the composition for promoting cell regeneration, and the composition is used for improving and treating testicular atrophy of rats. By taking activation and recovery of functions of spermatogonial stem cells as an entry point, a sPL preparation method capable of increasing secretion of three growth factors capable of promoting proliferation of spermatogonial stem cells, namely EGF, bFGF and IGF-1, and a BMSCs culture method for highly expressing miR-486-5p exosomes are found. The medicine is used for treating testicular atrophy.

Description

technical field [0001] The invention relates to the field of drugs for treating testicular atrophy, in particular to a composition for treating testicular atrophy and a preparation method thereof. Background technique [0002] Fertility issues are becoming increasingly important as humans live longer and the aging population increases. A gradual and steady decline in sperm count and quality and bioavailable or free serum testosterone (T) levels in men with age has been found to increase the incidence of testicular atrophy in men. Age-associated differences in human testes include a reduction in the volume or number of T-cell-producing Leydig cells, as well as changes in the morphology and number of Sertoli and germ cells, both of which may contribute to the age-related age-related changes in germ cells during spermatogenesis transsexual. These findings suggest that the mechanism of age-related decline in testicular function is intrinsic to the testis; however, testicular a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/28C12N5/0775C12N5/078A61P15/08A61K35/19
CPCC12N5/0644C12N5/0663A61K35/19A61K35/28A61P15/08C12N2509/00C12N2509/10C12N2501/91C12N2500/84A61K2300/00
Inventor 张天琦张怡刘春香孟令旗刘艳青
Owner 天晴干细胞股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap